Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue SUPPL. 1, 2009, Pages

  Bellmunt, Joaquim ^a   Calvo, Emiliano ^b   Castellano, Daniel ^c   Climent, Miguel Ángel ^d   Esteban, Emilio ^e   García Del Muro, Xavier ^f   González Larriba, José Luis ^g   Maroto, Pablo ^h   Trigo, José Manuel ⁱ  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CALCIUM; CREATININE; EVEROLIMUS; HYPERTENSIVE FACTOR; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE ACETATE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD PRESSURE; BODY MASS; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CAPILLARY LEAK SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMATURIA; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; LABORATORY TEST; LEUKOPENIA; LIVER FUNCTION TEST; LOSS OF FUNCTION MUTATION; LYMPHOCYTOPENIA; METASTASIS; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; NEPHRON SPARING SURGERY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OCCUPATIONAL EXPOSURE; PAIN; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RADIODIAGNOSIS; RASH; SIDE EFFECT; SMOKING; STOMATITIS; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR BIOPSY; URIC ACID BLOOD LEVEL; URINALYSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INDOLES; KIDNEY NEOPLASMS; LINEAR MODELS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 61349134778     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0955-3     Document Type: Conference Paper

References (81)

1. A Jemal R Siegel E Ward 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96
2. R Dhote N Thiounn B Debre 2004 Risk factors for adult renal cell carcinoma Urol Clin N Am 31 237 247
3. P Vineis M Alavanja P Buffler 2004 Tobacco and cancer: recent epidemiological evidence J Natl Cancer Inst 96 99 106
4. WH Chow G Gridley JF Fraumeni Jr 2000 Obesity, hypertension, and the risk of kidney cancer in men N Engl J Med 343 1305 1311
5. R Dhote M Pellicer-Coeuret N Thiounn 2000 Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention BJU Int 86 20 27
6. J Wagstaff 2006 New horizons in the treatment of renal cell cancer Ann Oncol 17 Suppl 10 x19 x22
7. MB Atkins MS Ernstoff RA Figlin 2007 Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference Clin Cancer Res 13 667s 670s
8. RE Banks P Tirukonda C Taylor 2006 Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer Cancer Res 66 2000 2011
9. L Schmidt FM Duh F Chen 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 16 68 73
10. LS Schmidt ML Nickerson MB Warren 2005 Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome Am J Hum Genet 76 1023 1033
11. RJ Motzer GB Bolger B Boston 2006 Kidney cancer. Clinical practice guidelines in oncology J Natl Compr Cancer Netw 4 1072 1081
12. Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook: TNM classification of malignant tumors. Springer, New York
13. BJ Drucker 2005 Renal cell carcinoma: current status and future prospects Cancer Treat Rev 31 536 545
14. PD Guinan NJ Vogelzang AM Fremgen 1995 Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee J Urol 153 901 903
15. AC Novick 2004 Laparoscopic and partial nephrectomy Clin Cancer Res 10 6322S 6327S
16. LJ Costa HA Drabkin 2007 Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies Oncologist 12 1404 1415
17. RC Flanigan SE Salmon BA Blumenstein 2001 Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655 1659
18. GH Mickisch A Garin H van Poppel 2001 Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966 970
19. JA Garcia BI Rini 2007 Recent progress in the management of advanced renal cell carcinoma CA Cancer J Clin 57 112 125
20. JP Kavolius DP Mastorakos C Pavlovich 1998 Resection of metastatic renal cell carcinoma J Clin Oncol 16 2261 2266
21. P Russo 2004 Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy Nat Clin Pract Urol 1 26 30
22. BI Rini V Shaw JE Rosenberg 2006 Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases Clin Genitourin Cancer 5 232 234
23. R Finney 1973 The value of radiotherapy in the treatment of hypernephroma-a clinical trial Br J Urol 45 258 269
24. H Juusela K Malmio O Alfthan 1977 Preoperative irradiation in the treatment of renal adenocarcinoma Scand J Urol Nephrol 11 277 281
25. M Kjaer PL Frederiksen SA Engelholm 1987 Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group Int J Radiat Oncol Biol Phys 13 665 672
26. M Kjaer P Iversen V Hvidt 1987 A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group Scand J Urol Nephrol 21 285 289
27. PJ Wersall H Blomgren I Lax 2005 Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma Radiother Oncol 77 88 95
28. LM Reichel S Pohar J Heiner 2007 Radiotherapy to bone has utility in multifocal metastatic renal carcinoma Clin Orthop Relat Res 459 133 138
29. LS Doh RJ Amato AC Paulino 2006 Radiation therapy in the management of brain metastases from renal cell carcinoma Oncology (Williston Park) 20 603 613 discussion 613, 616, 619-620 passsim
30. C Svedman P Sandstrom P Pisa 2006 A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma Acta Oncol 45 870 875
31. S Senan EF Smit 2007 Design of clinical trials of radiation combined with antiangiogenic therapy Oncologist 12 465 477
32. RJ Amato 2000 Chemotherapy for renal cell carcinoma Semin Oncol 27 177 186
33. JI Clark MB Atkins WJ Urba 2003 Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial J Clin Oncol 21 3133 3140
34. EM Messing J Manola G Wilding 2003 Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial J Clin Oncol 21 1214 1222
35. Pizzocaro G, Piva L, Costa A, Silvestrini R (1997) Adjuvant interferon (IFN) to radical nephrectomy in Robson's stages II and III renal cell cancer (RCC), a multicenter randomized study with some biological evaluations, 1997 ASCO annual meeting, abstract 1132
36. D Jocham A Richter L Hoffmann 2004 Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 594 599
37. E Jonasch C Wood P Tamboli 2008 Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings Br J Cancer 98 1336 1341
38. C Wood P Srivastava R Bukowski 2008 An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 145 154
39. A Skolarikos G Alivizatos P Laguna 2007 A review on follow-up strategies for renal cell carcinoma after nephrectomy Eur Urol 51 1490 1500 discussion 1501
40. SA Fuhrman LC Lasky C Limas 1982 Prognostic significance of morphologic parameters in renal cell carcinoma Am J Surg Pathol 6 655 663
41. J Sandlund E Oosterwijk K Grankvist 2007 Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma BJU Int 100 556 560
42. O Yaycioglu WW Roberts T Chan 2001 Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model Urology 58 141 145
43. MW Kattan V Reuter RJ Motzer 2001 A postoperative prognostic nomogram for renal cell carcinoma J Urol 166 63 67
44. I Frank ML Blute JC Cheville 2002 An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 2395 2400
45. A Zisman AJ Pantuck F Dorey 2001 Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 1649 1657
46. JJ Patard HL Kim JS Lam 2004 Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study J Clin Oncol 22 3316 3322
47. L Cindolo A de la Taille G Messina 2003 A preoperative clinical prognostic model for non-metastatic renal cell carcinoma BJU Int 92 901 905
48. L Cindolo JJ Patard P Chiodini 2005 Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study Cancer 104 1362 1371
49. A Ritchie G Griffiths M Parmar for the MRC Renal Cancer Collaborators 1999 Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators Lancet 353 14 17
50. G Fyfe RI Fisher SA Rosenberg 1995 Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 688 696
51. DF McDermott MM Regan JI Clark 2005 Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 133 141
52. JC Yang RM Sherry SM Steinberg 2003 Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 3127 3132
53. KA Margolin AA Rayner MJ Hawkins 1989 Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines J Clin Oncol 7 486 498
54. S Negrier D Perol A Ravaud 2007 Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial Cancer 110 2468 2477
55. RJ Motzer J Bacik BA Murphy 2002 Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289 296
56. RJ Motzer M Mazumdar J Bacik 1999 Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 2530 2540
57. RM Bukowski S Negrier P Elson 2004 Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group Clin Cancer Res 10 6310S 6314S
58. DB Mendel AD Laird X Xin 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337
59. RJ Motzer MD Michaelson BG Redman 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24
60. RJ Motzer BI Rini RM Bukowski 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524
61. RJ Motzer TE Hutson P Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124
62. RA Figlin TE Hutson P Tomczak MD Michaelson RM Bukowski S Négrier X Huang ST Kim I Chen RJ Motzer 2008 Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) J Clin Oncol 26 May 20 suppl abstr 5024
63. RA Hilger ME Scheulen D Strumberg 2002 The Ras-Raf-MEK-ERK pathway in the treatment of cancer Onkologie 25 511 518
64. H Akaza T Tsukamoto M Murai 2007 Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma Jpn J Clin Oncol 37 755 762
65. Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, Elting J, Pena C, Escudier B (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. In: 2007 ASCO annual meeting proceedings, part I. J Clin Oncol, vol 25, no. 18S (June 20 supplement), abstr 5023
66. B Escudier T Eisen WM Stadler 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134
67. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. In: 2007 ASCO annual meeting proceedings, part I. J Clin Oncol, vol 25, no. 18S (June 20 supplement), abstr 5025
68. BI Rini EJ Small 2005 Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 1028 1043
69. LG Presta H Chen SJ O'Connor 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599
70. RM Bukowski FF Kabbinavar RA Figlin 2007 Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 4536 4541
71. B Escudier A Pluzanska P Koralewski 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111
72. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena D, Ou S, Taylor J, Tanguay S, Dutcher J, Small EJ (2008) CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma, 2008 genitourinary cancers symposium, abstract no. 350
73. JC Yang L Haworth RM Sherry 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434
74. B Melichar P Koralewski A Ravaud 2008 First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma Ann Oncol 19 1470 1476
75. CC Hudson M Liu GG Chiang 2002 Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 7004 7014
76. D Del Bufalo L Ciuffreda D Trisciuoglio 2006 Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus Cancer Res 66 5549 5554
77. MB Atkins M Hidalgo WM Stadler 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918
78. G Hudes M Carducci P Tomczak 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281
79. J Jac RJ Amato S Giessinger S Saxena JP Willis 2008 A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy J Clin Oncol 26 May 20 suppl abstr 5113
80. RJ Motzer B Escudier S Oudard C Porta TE Hutson S Bracarda N Hollaender G Urbanowitz A Kay A Ravaud 2008 RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study J Clin Oncol 26 May 20 suppl abstr LBA5026
81. RJ Motzer J Bacik LH Schwartz 2004 Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 454 463